The TRAIL-R invalidation leads to more contrasting results: on one hand, the TRAIL-R deficiency was found to recapitulate the TRAIL deficient phenotype, since the loss of TRAIL-R in the lymphoma-prone Eμmyc genetic background significantly reduced the lymphoma-free survival and enhanced diethylnotrosamine (DEN)-induced hepatocarcinogenesis [81]. The gene discussed is TNFSF10; the disease is lymphoma.